Potential cost-savings may be considerable with management of hypertension according to updated US hypertension guidelines, but for women aged 35-44 years these benefits are unlikely

Commentary on: Moran AE, Odden MC, Thanataveerat A, et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med 2015;372:447–55. Context The number of people with hypertension is anticipated to increase despite greater awareness of the condition as a risk factor for cardiovascular disease (CVD) and more options for treatment. Clinical guidelines are evidence-based recommendations used to inform clinician practice when treating an individual patient. Regular updates of guidelines are important to ensure their ongoing relevance. Moran and colleagues investigated the potential cost implications in the USA if the management of hypertension aligned with the updated USA guidelines.1 Methods The authors used the updated Cardiovascular Disease Policy Model.2 Drug-treatment, monitoring costs and quality adjusted life years (QALYs) saved from prevention of CVD in untreated adults aged between 35 and 74 years managed according to the new guidelines from 2014...
Source: Evidence-Based Medicine - Category: Internal Medicine Authors: Tags: Health policy, Drugs: cardiovascular system, Stroke, Hypertension, Health economics, Health service research, Guidelines Economic analysis Source Type: research